Cargando…
Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose
Lung cancer has been the leading cause of cancer-related mortality in China in recent decades. Positron emission tomography-computer tomography (PET/CT) has been established in the diagnosis of lung cancer. (18)F-FDG is the most widely used PET tracer in foci diagnosis, tumor staging, treatment plan...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581209/ https://www.ncbi.nlm.nih.gov/pubmed/36275809 http://dx.doi.org/10.3389/fmed.2022.945602 |
_version_ | 1784812568353701888 |
---|---|
author | Zhu, Jing Pan, Fei Cai, Huawei Pan, Lili Li, Yalun Li, Lin Li, YunChun Wu, Xiaoai Fan, Hong |
author_facet | Zhu, Jing Pan, Fei Cai, Huawei Pan, Lili Li, Yalun Li, Lin Li, YunChun Wu, Xiaoai Fan, Hong |
author_sort | Zhu, Jing |
collection | PubMed |
description | Lung cancer has been the leading cause of cancer-related mortality in China in recent decades. Positron emission tomography-computer tomography (PET/CT) has been established in the diagnosis of lung cancer. (18)F-FDG is the most widely used PET tracer in foci diagnosis, tumor staging, treatment planning, and prognosis assessment by monitoring abnormally exuberant glucose metabolism in tumors. However, with the increasing knowledge on tumor heterogeneity and biological characteristics in lung cancer, a variety of novel radiotracers beyond (18)F-FDG for PET imaging have been developed. For example, PET tracers that target cellular proliferation, amino acid metabolism and transportation, tumor hypoxia, angiogenesis, pulmonary NETs and other targets, such as tyrosine kinases and cancer-associated fibroblasts, have been reported, evaluated in animal models or under clinical investigations in recent years and play increasing roles in lung cancer diagnosis. Thus, we perform a comprehensive literature review of the radiopharmaceuticals and recent progress in PET tracers for the study of lung cancer biological characteristics beyond glucose metabolism. |
format | Online Article Text |
id | pubmed-9581209 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95812092022-10-20 Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose Zhu, Jing Pan, Fei Cai, Huawei Pan, Lili Li, Yalun Li, Lin Li, YunChun Wu, Xiaoai Fan, Hong Front Med (Lausanne) Medicine Lung cancer has been the leading cause of cancer-related mortality in China in recent decades. Positron emission tomography-computer tomography (PET/CT) has been established in the diagnosis of lung cancer. (18)F-FDG is the most widely used PET tracer in foci diagnosis, tumor staging, treatment planning, and prognosis assessment by monitoring abnormally exuberant glucose metabolism in tumors. However, with the increasing knowledge on tumor heterogeneity and biological characteristics in lung cancer, a variety of novel radiotracers beyond (18)F-FDG for PET imaging have been developed. For example, PET tracers that target cellular proliferation, amino acid metabolism and transportation, tumor hypoxia, angiogenesis, pulmonary NETs and other targets, such as tyrosine kinases and cancer-associated fibroblasts, have been reported, evaluated in animal models or under clinical investigations in recent years and play increasing roles in lung cancer diagnosis. Thus, we perform a comprehensive literature review of the radiopharmaceuticals and recent progress in PET tracers for the study of lung cancer biological characteristics beyond glucose metabolism. Frontiers Media S.A. 2022-10-05 /pmc/articles/PMC9581209/ /pubmed/36275809 http://dx.doi.org/10.3389/fmed.2022.945602 Text en Copyright © 2022 Zhu, Pan, Cai, Pan, Li, Li, Li, Wu and Fan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Zhu, Jing Pan, Fei Cai, Huawei Pan, Lili Li, Yalun Li, Lin Li, YunChun Wu, Xiaoai Fan, Hong Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose |
title | Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose |
title_full | Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose |
title_fullStr | Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose |
title_full_unstemmed | Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose |
title_short | Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose |
title_sort | positron emission tomography imaging of lung cancer: an overview of alternative positron emission tomography tracers beyond f18 fluorodeoxyglucose |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581209/ https://www.ncbi.nlm.nih.gov/pubmed/36275809 http://dx.doi.org/10.3389/fmed.2022.945602 |
work_keys_str_mv | AT zhujing positronemissiontomographyimagingoflungcanceranoverviewofalternativepositronemissiontomographytracersbeyondf18fluorodeoxyglucose AT panfei positronemissiontomographyimagingoflungcanceranoverviewofalternativepositronemissiontomographytracersbeyondf18fluorodeoxyglucose AT caihuawei positronemissiontomographyimagingoflungcanceranoverviewofalternativepositronemissiontomographytracersbeyondf18fluorodeoxyglucose AT panlili positronemissiontomographyimagingoflungcanceranoverviewofalternativepositronemissiontomographytracersbeyondf18fluorodeoxyglucose AT liyalun positronemissiontomographyimagingoflungcanceranoverviewofalternativepositronemissiontomographytracersbeyondf18fluorodeoxyglucose AT lilin positronemissiontomographyimagingoflungcanceranoverviewofalternativepositronemissiontomographytracersbeyondf18fluorodeoxyglucose AT liyunchun positronemissiontomographyimagingoflungcanceranoverviewofalternativepositronemissiontomographytracersbeyondf18fluorodeoxyglucose AT wuxiaoai positronemissiontomographyimagingoflungcanceranoverviewofalternativepositronemissiontomographytracersbeyondf18fluorodeoxyglucose AT fanhong positronemissiontomographyimagingoflungcanceranoverviewofalternativepositronemissiontomographytracersbeyondf18fluorodeoxyglucose |